Current And Future Market Analysis Of Axial Spondyloarthritis Market 2024: Opportunity and Forecast
"The
Latest Research Report OpportunityAnalyzer: Axial Spondyloarthritis -
Opportunity Analysis and Forecast to 2024 - Event-Driven Update
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Ankylosing Spondylitis (AS) is an
autoimmune disease that causes inflammation of the sacroiliac joint
accompanied by pain and stiffness of the lower back, which typically
gets better with exercise. Ankylosis (fusion) of the spine is
typically a late-stage complication and has been nicknamed bamboo
spine, due to its appearance on X-ray. It is now recognized that the
pathological changes leading to ankylosis develop over time, and an
early stage of the disease, known as non-radiographic axial
spondyloarthritis (nr-axSpA) is characterized by the same symptoms of
inflammatory back pain without radiographic changes observed by
X-ray. Together, AS and nr-axSpA are known as axial spondyloarthritis
(axSpA). AS and nr-axSpA affect roughly 1.3 million and 700,000
individuals, respectively, in the seven major pharmaceutical markets
(7MM) (US, France, Germany, Italy, Spain, UK, and Japan) covered in
this report and the prevalence is expected to grow mainly due to
changes in diagnosis rates. The anti-TNFs have been effective in
treating the signs and symptoms of axSpA, however, there is a lack of
effective therapeutic classes, and no treatment options for patients
who have failed anti-TNF therapy, representing a key unmet need and
opportunities for drug developers.
Highlights
Key Questions Answered
- What are the preferred anti-TNFs
for and how will competition from pipeline agents and biosimilars
affect sales? Are rheumatologists across the 7MM expected to
prescribe biosimlars for axSpA?
- Will there be strong uptake of
pipeline agents and how will Novartiss Cosentyx, J&Js Stelara,
and Celgenes Otezla be used in the clinic?
- According to key opinion leaders
(KOLs), what are the most important unmet needs in axSpA? Will these
needs be addressed by pipeline agents? What needs will remain by the
end of the forecast period in 2024?
- How will disease awareness
change over the forecast period and will this affect diagnosis?
- How is non-radiographic axial
spondyloarthritis (nr-axSpA) treated and will the diagnosis and
treatment change over the next decade? Which drugs are expected to
gain label expansions into nr-axSpA?
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/419041
Key Findings
- Increased diagnosis and
treatment are key drivers in the axSpA market.
- Novartiss Cosentyx and J&Js
Stelara will address the unmet need for drugs with novel MOAs and
pose a threat to anti-TNFs, which are currently the only therapeutic
class beyond NSAIDs.
- Label expansions into AS and
nr-axSpA are expected to be an increasingly popular life-cycle
management strategy for pharmaceutical companies developing drugs
that target the immune system.
- Biosimilars are expected to
change the landscape for axSpA and will create pricing pressure in
the market.
Scope
- Overview of axial
spondyloarthritis (axSpA), including etiology, pathophysiology,
symptoms, and current treatment recommendations.
- Annualized axSpA market revenue,
annual cost of therapy and treatment usage pattern data from 2014 and
forecast for ten years to 2024, segmented by ankylosing spondylitis
(AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, R&D strategies, clinical trial design, and implications
for the axSpA market for branded drugs and biosimilars.
- Pipeline analysis: comprehensive
data split across different phases and emerging trends, specifically
Novartiss IL-17 inhibitor, Cosentyx; J&Js IL-12/IL-23 inhibitor,
Stelara; Celgenes novel PDE4 inhibitor, Otezla; and biosimilars.
- Analysis of the current and
future market competition in the global axSpA market. Clinical and
commercial benchmarking of promising pipeline products versus
standard of care treatments and competitive assessment of all
therapies for both AS and nr-axSpA . Insightful review of the key
industry drivers, restraints and challenges.
Reasons to buy
- Develop and design your
in-licensing and out-licensing strategies through a review of
pipeline products and technologies, and by identifying the companies
with the most robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the axSpA market.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global axSpA market in
the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
axSpA market from 2014-2024.
- Organize your sales and
marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments
and strategic partnerships.
Table of Contents
1 Table of Contents 9
1.1 List of Tables 14
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 19
2.3 Upcoming Related Reports 19
3 Disease Overview 20
3.1 Etiology and Pathophysiology
20
3.1.1 Etiology 20
3.1.2 Pathophysiology 21
3.2 Symptoms 22
3.2.1 Ankylosing Spondylitis 22
3.2.2 Non-radiographic Axial
Spondyloarthritis 24
Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/419041
4 Epidemiology 25
4.1 Risk Factors and Comorbidities
27
4.2 Global Trends 28
4.2.1 US 31
4.2.2 5EU 31
4.2.3 Japan 32
4.3 Forecast Methodology 32
4.3.1 Sources Used for Diagnosed
Prevalence of AS 35
4.3.2 Sources Used for Diagnosed
Prevalence of Nr-axSpA 38
4.3.3 Sources Used for the
Prevalence of HLA-B27 Seropositivity in Diagnosed AS 39
4.3.4 Sources Not Used 40
4.3.5 Forecast Assumptions and
Methods, Diagnosed Prevalent Cases of AS Base Scenario 41
4.3.6 Forecast Assumptions and
Methods, Diagnosed Prevalent Cases of Nr-axSpA Base Scenario 43
4.3.7 Forecast Assumptions and
Methods, HLA-B27 Seropositivity in Diagnosed AS 45
4.3.8 Forecast Assumptions and
Methods, Diagnosed Prevalent Cases of AS Alternative Scenario 45
4.3.9 Forecast Assumptions and
Methods, Diagnosed Prevalent Cases of Nr-axSpA Alternative Scenario
46
4.4 Epidemiological Forecast for
AS (2014-2024) Base Scenario 46
4.4.1 Diagnosed Prevalent Cases of
AS 46
4.4.2 Age-Specific Diagnosed
Prevalent Cases of Ankylosing Spondylitis 48
4.4.3 Sex-Specific Diagnosed
Prevalent Cases of AS 49
4.4.4 Age-Standardized Diagnosed
Prevalence of AS 51
4.4.5 Diagnosed Prevalent Cases of
Nr-axSpA 52
4.4.6 Prevalent Cases of HLA-B27
Seropositivity in Diagnosed AS Cases 54
4.5 Epidemiological Forecast for
AS (2014-2024) Alternative Scenario 57
4.5.1 Diagnosed Prevalent Cases of
AS 57
4.5.2 Diagnosed Prevalent Cases of
Nr-axSpA 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast
Insight 60
4.6.2 Limitations of the Analysis
61
4.6.3 Strengths of the Analysis 61
5 Current Treatment Options 63
5.1 Overview 63
5.2 Product Profiles Major Brands
65
5.2.1 Enbrel (etanercept) 65
5.2.2 Humira (adalimumab) 69
5.2.3 Remicade (infliximab) 73
5.2.4 Simponi (golimumab) 77
5.2.5 Cimzia (certolizumab pegol)
82
5.2.6 NSAIDs 86
5.2.7 Biosimilars 92
5.2.8 Other Therapies 99
6 Unmet Needs Assessment and
Oppportunity Analysis 100
6.1 Overview 100
6.2 Lack of Awareness 101
6.2.1 Unmet Need 101
6.2.2 Gap Analysis 103
6.2.3 Opportunity 105
6.3 Standardization of Diagnosis
and Early Treatment 105
6.3.1 Unmet Need 105
6.3.2 Gap Analysis 107
6.3.3 Opportunity 108
6.4 Drugs With Novel MOAs 109
6.4.1 Unmet Need 109
6.4.2 Gap Analysis 110
6.4.3 Opportunity 111
6.5 Recognition of Nr-axSpA 111
6.5.1 Unmet Need 111
6.5.2 Gap Analysis 113
6.5.3 Opportunity 114
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment